Author + information
- Received January 11, 1988
- Revision received March 9, 1988
- Accepted March 16, 1988
- Published online August 1, 1988.
- Sol Sherry, MD, FACC∗
- ↵∗Address for reprints: Soi Sherry, MD, Temple University School of Medicine, 3400 North Broad Street, Philadelphia, Pennsylvania 19140.
Thrombolytic therapy has now become established as a useful therapeutic measure for the immediate treatment of an acute evolving transmural infarction. Nevertheless, several important and fundamental aspects of a pharmacologic nature remain to be resolved. Prominent among these is whether or not fibrin specificity of a thrombolytic agent provides important benefits, and whether heparin therapy us commonly employed to prevent rethrombosis has been effective. Review of the available data raises serous questions as to the validity of current views and the appropriateness of prevailing trends.
☆ This study was supported by a grant from the UPS Foundation, Greenwich, Connecticut.
- Received January 11, 1988.
- Revision received March 9, 1988.
- Accepted March 16, 1988.